Ether derivatives useful as inhibitors of PDE4 isozymes

Details Ether derivatives useful as inhibitors of PDE4 isozymes Ether derivatives useful as inhibitors of PDE4 isozymes

2007-02-27

2007-02-27

Desai, Rita (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S284100, C546S270100, C546S281100

Reexamination Certificate

active

10918820

ABSTRACT:
This application is directed to compounds of the formulawherein j is 1; k is 0 or 1; m is 1, 2 or 3; n is 1 or 2; W1and W2are independently —O— or —S(═O)t—, where t is 0, 1, or 2; Y is ═C(R1a)—, where R1ais a member selected from the group consisting of H; F; Cl; CN; NO2; —(C1–C4)alkyl; —(C2–C4)alkynyl; fluorinated-(C1–C3)alkyl; fluorinated-(C1–C3)alkoxy; —OR16; and —C(═O)NR22aR22b; R22aand R22bare defined as set forth in the specification; —RAand RBare each a member independently selected from the group consisting of H; F; CF3; —(C1–C4)alkyl; —(C3–C7)cycloalkyl; phenyl; and benzyl; wherein said cycloalkyl, phenyl, and benzyl moieties are each independently substituted with 0 to 3 substituents R10, which is defined as set forth in the specification; R16and R17are defined as set forth in the specification; —RCand RDhave the same meaning as defined above for RAand RBexcept that one of them must be —H, and they are selected independently of each other and of RAand RB; R1and R2are each a member independently selected from the group consisting of H; F; Cl; CN; NO2; —(C1–C4)alkyl; —(C2–C4)alkynyl; fluorinated-(C1–C3)alkyl; OR16; and —C(═O)NR22aR22b; —R3is H; —(C1–C3)alkyl; phenyl; benzyl; or OR16; R4, R5, and R6are defined as set forth in the specification; J1and J2are each independently a moiety comprising a saturated or unsaturated six-membered monocyclic carbon ring; and D is a member independently selected from the group consisting of partial Formulas (1.1.1) through (1.1.5) as set forth in the specification; a pharmaceutically acceptable salt thereof; which are useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease.

REFERENCES:
patent: 4270946 (1981-06-01), Gutman
patent: 4692185 (1987-09-01), Michaely
patent: 4861891 (1989-08-01), Saccomano et al.
patent: 5552438 (1996-09-01), Christensen, IV
patent: 5602157 (1997-02-01), Christensen, IV
patent: 5614540 (1997-03-01), Christensen, IV
patent: 5863926 (1999-01-01), Christensen, IV et al.
patent: 5922557 (1999-07-01), Pon
patent: 6380218 (2002-04-01), Marfat et al.
patent: 6828333 (2004-12-01), Marfat et al.
patent: 0550900 (1992-12-01), None
patent: 0773024 (1997-05-01), None
patent: 0500989 (1998-12-01), None
patent: 2140772 (1973-01-01), None
patent: 2327675 (1999-02-01), None
patent: 7304775 (1995-11-01), None
patent: WO 9500139 (1995-01-01), None
patent: WO 9818796 (1998-05-01), None
patent: WO 9845268 (1998-10-01), None
patent: WO 9845628 (1998-10-01), None
patent: WO 9918793 (1999-04-01), None
patent: WO 9920280 (1999-04-01), None
patent: WO 9920625 (1999-04-01), None
patent: WO 0157025 (2001-08-01), None
patent: WO 0157036 (2001-08-01), None
Trophy, Theodore J. et al, “Phosphodiesterase IV Inhibitors as Therapy for Eosinophil-induced Lung Injury in Asthma,” Environmental Health Perspectives, vol. 102 Suppl. 10, Dec. 1994, pp. 79-84.
Duplantier, Allen J., et al., “Biarylcarboxylic Acids and -amides: Inhibition of Phosphodiesterase Type IV versus [3H]Rolipram Binding Activity and Their Relationship to Emetic Behavior in the Ferret, Journal of Medicinal Chemistry,” 1996, vol. 39, No. 1, pp. 120-125.
Schneider, Herbert H, et al, “Discriminative Stimulus Properties of the Stereoisomers of the Phosphodiesterase Inhibitor Rolipram,” Pharmacology Biochemistry and Behavior, vol. 50, No. 2, 1995, pp. 211-217.
Banner, Katherine H., et. al., “Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs,” British Journal of Pharmacology, 114, 1995, pp. 93-98.
Barnette, Mary S., et. al., “The Ability of Phosphodiesterase IV Inhibitors to Suppress Superoxide Production in Guinea Pig Eosinophils Is Correlated with Inhibition of Phosphodiesterase IV Catalytic Activity,” The Journal of Pharmacology and Experimental Therapeutics, 273, 1995 pp. 674-679.
Wright, Kathryn, F., et al., “Differential in vivo and in vitro bronchorelaxant activities of CP-80,633, a selective phosphodiesterase 4 inhibitor,”Can. J. Physiol. Pharmacol. 75, 1997, pp. 1001-1008.
Manabe, Haruhiko, “Anti-Inflammatory and Bronchodilator Properties of KF19514, a Phosphodiesterase 4 and 1 Inhibitor,” European Journal of Pharmacology, 332, 1997, pp. 97-107.
Ukita, Tatsuzo, et. al., Novel, Potent, and Selective Phosphodiesterase-4 Inhibitors as Antiasthmatic Agents: Synthesis and Biological Activities of a Series of 1-Pyridylnaphthalene Derivatives, J. Med. Chem, 48, 1999, pp. 1088-1099.
Compton, CH, et. al., The Efficacy of Ariflo™ (SB 207499, A Second Generation, Oral PDE4 Inhibitor, In Patients with COPD, Am. J. Respir. Crit. Care Med., 159, 1999.
Leeman, Marc M.D., et. al., “Reduction in Pulmonary Hypertension and in Airway Resistances by Enoximone (MDL 17,043) in Decompensated COPD*,” Chest, 91, 1987, pp. 662-666.
Rabe, K.F., et. al., “Identification of PDE Isozymes in Human Pulmonary Artery and Effect of Selective PDE Inhibitors,” Am. J. Physiol, 266 (LCMP 10), 1994, pp. L536-L543.
Hughes, Bernadette, et. al., PDE 4 inhibitors: the use of molecular cloning in the design and development of novel drugs, Drug Discovery Today, Science Direct, 2(3), 1997, pp. 89-101.
Banner, K.H., et. al., “The Effect of Selective Phosphodiesterase Inhibitors in Comparison with other Anti-asthma Drugs on Allergen-induced Eosinophilia in Guinea-pig Airways,” Pulmonary Pharmacology, 8, 1995, pp. 37-42.
Raebum, David, et.al., “Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase typed IV inhibitor,” Br, J. Pharmacol., 113, 1994, pp. 1423-1431.
Karlsson, J.A., et. al., “Anti-Inflammatory Effects of the Novel Phosphodiesterase IV Inhibitor RP 73401,” Int. Arch Allergy Immunol, 107, 1995, pp. 425-426.
Escott, K.J., et. al., Pharmacological Profiling of Phosphodiesterase, 4 (PDE4) Inhibitors and Analysis of the Therapeutic Ratio in Rats and Dogs, Br, J. Pharmacol, 123 (Proc suppl.) 1998 40P.
Landells, L.J., et. al., “Oral Administration of the Phosphodiesterase (PDE) 4 Inhibitor, V11294A Inhibits Ex-Vivo Agonist-induced Cell Activation,” Eur. Resp. J., 12 (Suppl. 28), 362s, 1998, P2393.
Gale, D.D., et. al., “Pharmacodynamic-Pharmacokinetic (PD/PK) Profile of the Phosphodiesterase (PDE)4 Inhibitor, V11294A, in Human Volunteers,” Am. J. Respir. Crit Care Med., 159, A611, 1999, pp. A108.
Montana, J., et. al., “Activity of D4418, A Novel Phosphodiesterase 4 (PDE4) Inhibitor, Effects in Cellular and Animal Models of Asthma and Early Clinical Studies,” Am. J. Respir. Crit., Care Med., 159, A108, 1999, pp. A624.
Cavalla, D., et. al., “Activity of V11294A, A Novel Phosphodiesterase 4 (PDE4) Inhibitor, In Cellular and Animal Models of Asthma,” Am. J. Respir. Crit. Care Med. 155, 1997, pp. A660.
Pascal, Y., et. al., “Synthesis and Structure,-activity Relationships of 4-oxo-1 pheyl-3,4,5,7-Tetrahydro-[1,4]Diazepino[6,7,1-HI]Indolines: Novel PDE4 Inhibitors,” 215thACS, MEDI, 50, 1998.
Burnouf, C., et. al., “Pharmacology of the Novel Phosphodiesterase Type 4 Inhibitor, CI-1018,” 215thACS, MEDL 008, 1998.
Mueller, George W., et. al., N-Phthaloyl-β- Aryl- β- Amino Derivatives Potent TNF-α And PDE4 Inhibitors, MEDI, 299, 1999.
Mueller, George W., et. al., “Thalidomide Analogs and PDE4 Inhibition,” Bioorganic & Medicinal Chemistry Letters, 8, 1998, pp. 2669-2674.
Takayama, K., “Synthetic Studies on Selective Type IV Phosphodiesterase (PDE IV) Inhibitors,” MEDI 245, 1997.
Gordon, T., et. al., “Anti-Inflammatory Eff

Affiliated with

Also associated with

Rating

Ether derivatives useful as inhibitors of PDE4 isozymes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ether derivatives useful as inhibitors of PDE4 isozymes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ether derivatives useful as inhibitors of PDE4 isozymes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3833083